iShares NASDAQ US Biotechnology UCITS ETF (ETR:2B70)

Germany · Delayed Price · Currency is EUR

9.15

-0.02 (-0.17%)

Sep 23, 2026, 4:07 PM CET

Assets	982.10M
Expense Ratio	0.37%
PE Ratio	24.97
Dividend (ttm)	n/a
Dividend Yield	n/a
Ex-Dividend Date	n/a
Payout Frequency	n/a
Payout Ratio	n/a
1-Year Return	+52.52%

Volume	136,261
Open	9.17
Previous Close	9.16
Day's Range	9.13 - 9.19
52-Week Low	5.86
52-Week High	9.25
Beta	0.23
Holdings	258
Inception Date	Oct 19, 2017

About 2B70

iShares NASDAQ US Biotechnology UCITS ETF is an exchange traded fund launched by BlackRock Asset Management Ireland Limited. It is managed by BlackRock Advisors (UK) Limited. The fund invests in the public equity markets of the United States. It seeks to invest in the stocks of companies operating in the biotechnology and pharmaceuticals sector. The fund invests in the stocks of companies across all market capitalizations. It seeks to replicate the performance of the NASDAQ Biotechnology Index, by employing representative sampling methodology. iShares NASDAQ US Biotechnology UCITS ETF was formed on October 19, 2017 and is domiciled in Ireland.

Asset Class Equity

Category Health Care

Region North America

Stock Exchange Deutsche Börse Xetra

Ticker Symbol 2B70

Provider iShares

Index Tracked NASDAQ / Biotechnology

Performance

2B70 had a total return of 52.52% in the past year, including dividends. Since the fund's inception, the average annual return has been 10.03%.

Top 10 Holdings

44.60% of assets

Name	Symbol	Weight
Vertex Pharmaceuticals Incorporated	VRTX	8.01%
Amgen Inc.	AMGN	7.83%
Gilead Sciences, Inc.	GILD	7.79%
Regeneron Pharmaceuticals, Inc.	REGN	5.38%
Moderna, Inc.	MRNA	4.15%
Revolution Medicines, Inc.	RVMD	2.77%
Illumina, Inc.	ILMN	2.46%
Alnylam Pharmaceuticals, Inc.	ALNY	2.17%
Biogen Inc.	BIIB	2.14%
Roivant Sciences Ltd.	ROIV	1.91%

View More Holdings